Browsing by Author "Ozyar, E."
Now showing 1 - 12 of 12
- Results Per Page
- Sort Options
Item A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era(2022-01-01) Bossi, P.; Alberti, A.; Zamparini, M.; Orlandi, E.; Grisanti, S.; Trama, A.; Resteghini, C.; Nin, R. Mesia; Mohamad, I.; Ozyar, E.; Buglione, M.; Airoldi, M.; Vecchio, S.; Livi, L.; Cirauqui, B. Cirauqui; El-Sherify, M.; Ursino, S.; Argiris, A.; Galiana, I. Linares; Licitra, L. F.Item Clinical outcome and toxicity of stereotactic ablative radiotherapy to centrally located tumors.(ELSEVIER IRELAND LTD, 2018-01-01) Atalar, B.; Sahin, B.; Mustafayev, T. Zoto; Gungor, G.; Aydin, G.; Yapici, B.; Ozyar, E.Item Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problem(OXFORD UNIV PRESS, 2018-01-01) Guler, O. C.; Onal, C.; Ozyar, E.Item Correlation between PET/CT primary tumor FDG uptake and lymph node metastases in cervical cancer(ELSEVIER IRELAND LTD, 2017-01-01) Ugurluer, G.; Atalar, B.; Ikizler, H. A. Saran; Sozer, N.; Kibar, M.; Serin, M.; Ozyar, E.Item Dosimetric and Clinical Evaluation of Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Treatment of Adrenal Metastases(2021-01-01) Ugurluer, G.; Serkizyan, A.; Mustafayev, T. Zoto; Atalar, B.; Abacioglu, M. U.; Gungor, G.; Ozyar, E.Item Human-Level Precision Upper Abdominal OAR Contouring With Anatomically Preserving Deep Learning During Magnetic Resonance Imaging Guided Adaptive Radiotherapy (MRgRT)(2020-01-01) Gungor, G.; Michalet, M.; Lombard, A.; Roque, T.; Atalar, B.; Temur, B.; Serbez, I.; Azria, D.; De Vitry, L.; Riou, O.; Paragios, N.; Ozyar, E.; Fenoglietto, P.Item Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (SMART) With Median Biologically Effective Dose of 100 Gy10 for Oligometastases(2022-01-01) Chuong, M. D.; Herrera, R.; Mustafayev, T. Z.; Gungor, G.; Ugurluer, G.; Atalar, B.; Kotecha, R.; Hall, M. D.; Rubens, M.; Mittauer, K. E.; Contreras, J.; Gutierrez, A.; Kalman, N. S.; Alvarez, D.; Romaguera, T.; McCulloch, J.; Garcia, J.; Kaiser, A.; Mehta, M. P.; Ozyar, E.Item Outcome and prognosticators in adult patients with medulloblastoma: a Rare Cancer Network study(ELSEVIER IRELAND LTD, 2016-01-01) Atalar, B.; Ozsahin, M.; Call, J.; Napieralska, A.; Kamer, S.; Salvador, V.; Erpolat, P.; Negretti, L.; Ramstad, Y. L.; Onal, C.; Akyurek, S.; Ugurluer, G.; Baumert, B.; Servagi-Vernat, S.; Miller, R. C.; Ozyar, E.; Sio, T.Item ROBOTIC STEREOTACTIC HYPOFRACTIONATED RADIOTHERAPY IN MENINGIOMAS(OXFORD UNIV PRESS INC, 2014-01-01) Sahin, B.; Atalar, B.; Aydin, G.; Gungor, G.; Yapici, B.; Ozyar, E.Item Time Analysis in Magnetic Resonance Image-Guided Radiotherapy Workflow(2019-01-01) Mustafayev, T. Z.; Sahin, B.; Gungor, G.; Aydin, G.; Serbez, I.; Teymur, B.; Gur, G.; Arabaci, G.; Atalar, B.; Yapici, B.; Abacioglu, U.; Agaoglu, F.; Sengoz, M.; Ozyar, E.Item Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study(OXFORD UNIV PRESS, 2011-01-01) Onal, C.; Li, Y. X.; Miller, R. C.; Poortmans, P.; Constantinou, N.; Weber, D. C.; Atasoy, B. M.; Igdem, S.; Ozsahin, M.; Ozyar, E.Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74\% and 71\%, respectively, and the disease-free survival (DFS) rates were 68\% and 64\%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.Item Uncommon tumours of the nasopharynx(SPRINGER-VERLAG FRANCE, 2010-01-01) Ozyar, E.; Gueltekin, M.